ArticleImmunity, inflammation and disease2022
Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine.
Article in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- Article
- Article
- A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation.NPJ vaccines · 2024Article
- Evaluating long-term antibody responses to booster doses of COVID-19 vaccines in the Pakistani population.Pakistan journal of medical sciences · 2024Article
- Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.Heliyon · 2023Article
- Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: A prospective observational study.Health science reports · 2023Article
- Pernicious Anemia Following COVID-19 Vaccination: A Report of Two Cases.International journal of hematology-oncology and stem cell research · 2023Article
- Article
- Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity.Acta pharmaceutica Sinica. B · 2023Article
- Article
- Review
- COVID-19 Vaccines, Effectiveness, and Immune Responses.International journal of molecular sciences · 2022Review
- Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.Vaccine: X · 2022Article
- A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines.Cell reports. Medicine · 2022Article
- Article
- Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine.Immunity, inflammation and disease · 2022Article
- Article
- Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.International journal of biological sciences · 2022Review
- IgG antibody response by ELISA using Wuhan and Lambda variant antigens in BBIBP-CORV vaccinated health care workers.Revista peruana de medicina experimental y salud publicaArticle
Corrections and comments
- Update of
Authors and funding
31 authors at 2 institutions in 3 countries.
Funding
Abstract
backgroundTo determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan individuals.
methodsSARS-CoV-2 specific total antibodies were measured in 20-39 years (n = 61), 40-59 years (n = 120) and those >60 years of age (n = 22) by enzyme-linked immunosorbent assay, 12 weeks after the second dose of the vaccine. Angiotensin-converting enzyme 2 (ACE2) receptor blocking antibodies (ACE2R-Ab), antibodies to the receptor-binding domain (RBD) of the ancestral virus (WT) and variants of concern, were measured in a sub cohort. T cell responses and memory B cell responses were assessed by ELISpot assays.
resultsA total of 193/203 (95.07%) of individuals had detectable SARS-CoV-2 specific total antibodies, while 67/110 (60.9%) had ACE2R-Ab. A total of 14.3%-16.7% individuals in the 20-39 age groups had detectable antibodies to the RBD of the WT and variants of concern, while the positivity rates of those ≥60 years of age was <10%. A total of 14/49 (28.6%) had Interferon gamma ELISpot responses to overlapping peptides of the spike protein, while memory B cell responses were detected in 9/20 to the S1 recombinant protein. The total antibody levels and ACE2R-Ab declined from 2 to 12 weeks from the second dose, while ex vivo T cell responses remained unchanged. The decline in ACE2R-Ab levels was significant among the 40-59 (p = .0007) and ≥60 (p = .005) age groups.
conclusionsAntibody responses declined in all age groups, especially in those ≥60 years, while T cell responses persisted. The effect of waning of immunity on hospitalization and severe disease should be assessed by long term efficacy studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.